AVTE Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

$13.04  -0.02 (-0.15%)
As of 12/03/2021 12:01:48 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/30/2021
Outstanding shares:  24,410,393
Average volume:  88,824
Market cap:   $327,343,370
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    008064107
ISIN:        US0080641071
Sedol:      BLR8K47
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.77
PS ratio:   0.00
Return on equity:   -10.23%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy